References
- Seetal D, David H, Gin S M, Michael B. To combine or not to combine? A literature review of antidepressant combination therapy Meta-Analysis J Affect Disord. 2005 Dec;89(1-3):1-11. doi: 10.1016/j.jad.2005.08.012. Epub 2005 Sep 16
- Grote N.K. Difficult-to-treat depression: the role of contexts and comorbidities. Biol. Psychiatry 2003 2003 Apr 15;53(8):660-70. doi: 10.1016/s0006-3223(03)00006-4.
- Nelson J.C. . Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol. Psychiatry 2004 Feb 1;55(3):296-300.doi: 10.1016/j.biopsych.2003.08.007.
- Perlis H.S .Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression Psychosomatics. 2004 May-Jun;45(3):224-9.doi: 10.1176/appi.psy.45.3.224.
- Jonathan H, Alexander D, Bushor T, Beatare CH. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression JAMA Psychiatry. 2022 Feb 16; 79(4): 300–312. doi: 10.1001/jamapsychiatry.2021.4313
- Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder: third edition. Published October 2010. Accessed January 11 2022 https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
- American Psychological Association. Depression treatments for adults. Published August 2019. Accessed October 13, 2020. https://www.apa.org/depression-guideline/adults
- Xiao L, Zhu X, Gillespie A, et al. Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial. Psychol Med. 2021; 51(7): 1166–1174. doi: 10.1017/S0033291719004069 [DOI] [PubMed] [Google Scholar]
- Pierre B, Ward E, Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study Publication: American Journal of Psychiatry 2021; 5(6): 12–321.
- Pigott HE, Kim T, Xu C, Kirsch I, Amsterdam J. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol. BMJ Open. 2023 Jul 25; 13(7): e063095. doi: 10.1136/bmjopen-2022-063095
- Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME: Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008; 63:424–434
- Wang Qi,, Liang Yao, M Yaolong Combination Antidepressant Therapy vs Monotherapy—Further Considerations JAMA Psychiatry. 2022; 79(8): 831–832. doi:10.1001/jamapsychiatry.2022.1391
- Elisa F 1, Amir H, Pierre B Treatment of depression: antidepressant monotherapy and combination therapy Psychiatry (Edgmont) . 2007 Nov; 4(11): 25–7.
- Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: Implications for clinical practice. Am J Psychiatry. 2006; 163: 28–40. - PubMed
- Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRs for depression. N Eng J Med. 2006; 354: 1243–52. - PubMed
- Evans DL, Charney DS. Mood disorders and medical illness: A major public health problem. Biol Psychiat. 2003; 54: 177–80. - PubMed
- Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011; 21(9): 655–679.